Does empagliflozin improve myocardial oxidative stress injury and cardiac fibrosis in diabetic mice?
Diabetic mice
Empagliflozin
Myocardial oxidative stress injury and cardiac fibrosissurrogate
Empagliflozin shows promise for the prevention and treatment of diabetic cardiomyopathy by reducing myocardial oxidative stress and fibrosis in a preclinical model.
Glycaemic control with empagliflozin significantly ameliorated myocardial oxidative stress injury and cardiac fibrosis in diabetic mice. Taken together, these results indicate that the empagliflozin is a promising agent for the prevention and treatment of diabetic cardiomyopathy.
Building similarity graph...
Analyzing shared references across papers
Loading...
Chenguang Li
University of British Columbia
Jie Zhang
Steno Diabetes Centers
Mei Xue
Tianjin University of Science and Technology
SHILAP Revista de lepidopterología
Cardiovascular Diabetology
Tianjin Medical University
Building similarity graph...
Analyzing shared references across papers
Loading...
Li et al. (Sat,) studied this question.
synapsesocial.com/papers/69d573009d980f6498ccb239 — DOI: https://doi.org/10.1186/s12933-019-0816-2